Cell Therapy Bioprocessing
The production of cell therapies starting from the cell source through manufacturing to final implantation in the clinic - a whole bioprocessing approach
18 - 20 February 2013
Cell therapy is emerging as a significant therapeutic modality with its own unique challenges including scalable manufacturing. The ability to bioprocess cells for therapy in safe, robust and cost effective manner is critical to the success of the industry. To achieve this goal, there is a need to understand the effect of the whole bioprocess sequence from cell sourcing and isolation, through expansion, differentiation and implantation into the patient. Through a series of lectures and problem solving case studies stem cells (embryonic, fetal and adult), adult cells and tissueengineered constructs, will be discussed.
"Inspirational talks and excellent in-depth discussions with presenters" - Muna Whyte, Smith & Nephew
"I really enjoyed the presentations on the automation of tissue culture procedures. I've always heard about the potential of this, but was amazed by the videos that were shown." - Cathy Oliveira, ReNeuron
Previous companies attending have included Avecia, Biosynergy, Capsant, CELS, GE Healthcare AB, InterMark, Johnson & Johnson, MRC, NovaThera, Odontis, Plasticell, Proval Technologies, ReNeuron, Sanofi-Aventis, Smith & Nephew, TEOX and Wyeth.
Who should attend?
Stakeholders in the cell-based therapy sector who plan or are progressing a cell or tissue-engineered therapy through translation and into routine clinical practice. The course comprehensively covers both the service (autologous) and universal (allogenic) approach to whole bioprocessing.
Programme
Stem Cells; Sourcing, Characterisation and Banking
• Deriving a human embryonic stem cell line
• UK Stem Cell Bank Stem Cell Expansion
• Automation of human embryonic stem cell expansion and differentiation
• Contract manufacture and stem cells
Cell Therapies
• Embryonic cells
• Fetal and adult stem cells
• Adult cells
Tissue Engineering
• Tissue engineering in a commercial environment - allogeneic therapies
• Challenges of autologous tissue engineering
Case Studies: Adult Stem Cell Therapy and Engineered-Tissue Therapy
• Defining the bioprocess from cell sourcing to patient implantation
• Meeting regulatory and economic challenges
• Allogeneic versus autologous approaches
Previous expert speakers include
Christopher Bravery, Consulting on Advanced Biologicals
Gary Brooke, ReNeuron
Julie Daniels, Moorfields Eye Hospital
Lucia D’Apote, EMA
Rosemary Drake, TAP Biosystems
Charles Hunt, UK Stem Cell Bank, NIBSC
Paul Kemp, Intercytex
Mark Lowdell, Royal Free Hospital
Kenny Pollock, ReNeuron
Mike Scott, Addenbrooke’s Hospital
Martin Smith, eXmoor pharma concepts
Glyn Stacey, UK Stem Cell Bank, NIBSC
Mike Watts, UCL Hospitals
Module Leaders
Chris Mason Farlan Veraitch and Ivan Wall, UCL
A networking dinner will be held on the first evening.
The module costs £1300, with a £100 discount if you register and pay before 7 January.
Download the Flyer
Page last modified on 01 aug 12 14:20
